Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Account Payables
Amounts the company owes suppliers for goods and services received.
Opus Genetics, Inc.NASDAQ: IRD
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 82.0% from a year ago
Account payables stood at $4.42M at the end of Q1 FY2026, up 82.0% from a year earlier and up 34.3% from the prior quarter. Over 3 fiscal years it compounded at +45.5% a year.
Context
- Account payables amounted to 6.6% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +82.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 3.29M USD
- Year-over-year change
- +4.6%
- 4-year CAGR
- +20.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.29M | +4.6% |
| FY2024 | 2024-12-31 | 3.15M | +46.2% |
| FY2023 | 2023-12-31 | 2.15M | +101.4% |
| FY2022 | 2022-12-31 | 1.07M | -32.5% |
| FY2021 | 2021-12-31 | 1.58M | — |
Account Payables vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 account payables of $4.42M is the 2nd highest of the 10 companies compared; the peer median is $2.34M.
- Its year-over-year change of +82.0% is the 3rd highest of 10, against a peer median of +10.7%.
- Account payables amounts to 6.6% of total assets for IRD, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $71.08M | +10.7% | +26.6% | 38.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.42M | +82.0% | +45.5% | 6.6% |
| Mar 2026 | $3.95M | +28.2% | +25.3% | 13.3% | |
| Mar 2026 | $3.85M | +111.4% | -29.7% | 10.7% | |
| Mar 2026 | $2.5M | -43.9% | +38.7% | 0.9% | |
| Mar 2026 | $2.34M | +7.8% | -54.1% | 2.0% | |
| Mar 2026 | $1.99M | -64.0% | -50.1% | 4.0% | |
| Mar 2026 | $1.66M | +56.7% | -30.4% | 1.2% | |
| Mar 2026 | $1.42M | -38.8% | -26.1% | 0.6% | |
| Mar 2026 | $793K | +177.3% | -30.9% | 0.4% | |
| Peer median (excluding IRD) | $2.34M | +10.7% | -29.7% | 2.0% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.